Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAE in Localized TNBC Insensitive to Standard Chemo
NCT02456857Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2016
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, bevacizumab and everolimus in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Residual Cancer Burden Status up to 3 years. Started Jan 2016; status: completed.
02
Drugs
pegylated liposomal doxorubicinbevacizumabeverolimus
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02456857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02456857.